Publications - Robert R . McWilliams, M.D.

Back to Research Profile

1. McWilliams RR, Petersen GM, Rabe KG, Holtegaard LM, Lynch PJ, Bishop MD, Highsmith WE Jr. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations and risk for pancreatic adenocarcinoma. Cancer 2009 Nov 02. [Epub ahead of print]
   View PubMed
2. Couch FJ, Wang X, McWilliams RR, Bamlet WR, de Andrade M, Petersen GM. Association of breast cancer susceptibility variants with risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2009 Nov; 18(11):3044-8. Epub 2009 Oct 20.
   View PubMed
3. Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, Fuchs CS, Petersen GM, Arslan AA, Bueno-De-Mesquita HB, Gross M, Helzlsouer K, Jacobs EJ, LaCroix A, Zheng W, Albanes D, Bamlet W, Berg CD, Berrino F, Bingham S, Buring JE, Bracci PM, Canzian F, Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet 2009 Sep; 41(9):986-NIL_47.
   View PubMed
4. Dewald GW, Smyrk TC, Thorland EC, McWilliams RR, Van Dyke DL, Keefe JG, Belongie KJ, Smoley SA, Knutson DL, Fink SR, Wiktor AE, Petersen GM. Fluorescence in situ hybridization to visualize genetic abnormalities in interphase cells of acinar cell carcinoma, ductal adenocarcinoma, and islet cell carcinoma of the pancreas. Mayo Clin Proc 2009 Sep; 84(9):801-10.
   View PubMed
5. McWilliams RR, Bamlet WR, de Andrade M, Rider DN, Couch FJ, Cunningham JM, Matsumoto ME, Rabe KG, Hammer TJ, Petersen GM. Polymorphic variants in hereditary pancreatic cancer genes are not associated with pancreatic cancer risk. Cancer Epidemiol Biomarkers Prev 2009 Sep; 18(9):2549-52. Epub 2009 Aug 18.
   View PubMed
6. Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, Fuchs CS, Petersen GM, Arslan AA, Bueno-de-Mesquita HB, Gross M, Helzlsouer K, Jacobs EJ, LaCroix A, Zheng W, Albanes D, Bamlet W, Berg CD, Berrino F, Bingham S, Buring JE, Bracci PM, Canzian F, Clavel-Chap Genome-wide association study identifies ABO blood group susceptibility variants for pancreatic cancer. Nat Genet 2009 Aug 2. [Epub ahead of print]
   View PubMed
7. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM, McWilliams RR. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009 Aug 1; 27(22):3677-83. Epub 2009 May 26.
   View PubMed
8. McWilliams RR, Petersen GM. Overweight, Obesity, and Pancreatic Cancer: Beyond Risk Alone. JAMA Invited Editorial 2009 Jun 24; 301(24):2592-2593.
   View PubMed
9. McWilliams RR, Bamlet WR, de Andrade M, Rider DN, Cunningham JM, Petersen GM. Nucleotide excision repair pathway polymorphisms and pancreatic cancer risk: evidence for role of MMS19L. Cancer Epidemiol Biomarkers Prev 2009 Apr; 18(4):1295-302. Epub 2009 Mar 24.
   View PubMed
10. Markovic SN, Erickson LA, Flotte TJ, Kottschade LA, McWilliams RR, Jakub JW, Farley DR, Tran NV, Schild SE, Olivier KR, Vuk-Pavlovic S, Sekulic A, Weenig RH, Pulido JS, Quevedo JF, Vile RG, Wiseman GA, Stoian I, Pittelkow MR, Melanoma Study Group of the Metastatic malignant melanoma. G Ital Dermatol Venereol 2009 Feb; 144(1):1-26.
    View PubMed
11. Markovic SN, Erickson LA, Flotte TJ, Kottschade LA, McWilliams RR, Jakub JW, Farley DR, Tran NV, Schild SE, Olivier KR, Vuk-Pavlovic S, Sekulic A, Weenig RH, Pulido JS, Quevedo JF, Vile RG, Wiseman GA, Stoian I, Pittelkow MR. Metastatic malignant melanoma. G Ital Dermatol Venereol 2009 Feb; 144(1):1-26.
    View PubMed
12. Halfdanarson TR, Wang L, Bamlet WR, de Andrade M, McWilliams RR, Cunningham JM, Petersen GM. Mitochondrial genetic polymorphisms do not predict survival in patients with pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2008 Sep; 17(9):2512-3.
    View PubMed
13. Thompson RH, Zang X, Lohse CM, Leibovich BC, Slovin SF, Reuter VE, Cheville JC, Blute ML, Russo P, Kwon ED, Allison JP. Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Res 2008 Aug 1; 68(15):6054-8.
    View PubMed
14. Corsini MM, Miller RC, Haddock MG, Donohue JH, Farnell MB, Nagorney DM, Jatoi A, McWilliams RR, Kim GP, Bhatia S, Iott MJ, Gunderson LL. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). J Clin Oncol 2008 Jul 20; 26(21):3511-6.
    View PubMed
15. McWilliams RR, Bamlet WR, Cunningham JM, Goode EL, de Andrade M, Boardman LA, Petersen GM. Polymorphisms in DNA repair genes, smoking, and pancreatic adenocarcinoma risk. Cancer Res 2008 Jun 15; 68(12):4928-35. Epub 2008 Jun 10.
    View PubMed
16. Galanis E, Carlson SK, Foster NR, Lowe V, Quevedo F, McWilliams RR, Grothey A, Jatoi A, Alberts SR, Rubin J. Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer. Mol Ther 2008 May; 16(5):979-84. Epub 2008 Mar 18.
    View PubMed
17. McWilliams RR, Rao RD, Buckner JC, Link MJ, Markovic S, Brown PD. Melanoma-induced brain metastases. Expert Rev Anticancer Ther 2008 May; 8(5):743-55.
    View PubMed
18. McKean H, Looker S, Hartmann LC, Hayman SR, Kaur JS, McWilliams RR, Peethambaram PP, Stahl JF, Jatoi A. Are cancer survivors/patients knowledgeable about osteoporosis? Results from a survey of 285 chemotherapy-treated cancer patients and their companions. J Nutr Educ Behav 2008 May-Jun; 40(3):144-8.
    View PubMed
19. Melanoma Study Group of the Mayo Clinic Cancer Center, Celis E. Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction. Cancer 2007 Jul 1; 110(1):203-14.
    View PubMed
20. Melanoma Study Group of the Mayo Clinic Cancer Center, Celis E. Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction. Cancer 2007 Jul 1; 110(1):203-14.
    View PubMed
21. Markovic SN, Suman VJ, Rao RA, Ingle JN, Kaur JS, Erickson LA, Pitot HC, Croghan GA, McWilliams RR, Merchan J, Kottschade LA, Nevala WK, Uhl CB, Allred J, Creagan ET. A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol 2007 Jun; 30(3):303-9.
    View PubMed
22. Markovic SN, Suman VJ, Rao RA, Ingle JN, Kaur JS, Erickson LA, Pitot HC, Croghan GA, McWilliams RR, Merchan J, Kottschade LA, Nevala WK, Ulh CB, Allerd J, Creagan ET. A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol 2007 June; 30(3):303-9.
    View PubMed
23. McWilliams RR, Goetz MP, Morlan BW, Salim M, Rowland KM, Krook JE, Ames MM, Erlichman C. Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer. Clin Colorectal Cancer 2007 May; 6(7):516-21.
    View PubMed
24. Alberts SR, Sande JR, Foster NR, Quevedo FJ, McWilliams RR, Kugler JW, Fitch TR, Jaslowski AJ. Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943. J Gastrointest Cancer 2007; 38(2-4):87-94. Epub 2008 Nov 21.
    View PubMed
25. Markovic SN, Suman VJ, Rao RA, Ingle J, Kaur JS, Erickson LA, Pitot HC, Croghan GA, McWilliams RR, Merchan J, Kottschade LA, Nevala WK, Uhl CB, Allred J, Creagan ET. A Phase II Study of ABT-510 (A thrombospondin-1 analog) for the treatment of metastatic melanoma. American Journal of Clinical ONcology 2007; In Press.
26. McWilliams RR, Bamlet WR, Rabe KG, Olson JE, de Andrade M, Petersen GM. Association of family history of specific cancers with a younger age of onset of pancreatic adenocarcinoma. Clin Gastroenterol Hepatol 2006 Sep; 4(9):1143-7. Epub 2006 Jul 24.
    View PubMed
27. McWilliams RR, Rao RD, Brown PD, Link MJ, Buckner JC. Treatment options for brain metastases from melanoma. Expert Review of Anticancer Therapy 2005 Oct; 5(5):809-20.
    View PubMed
28. McWilliams RR, Erlichman C. Novel therapeutics in colorectal cancer. Dis Colon Rectum 2005 Aug; 48(8):1632-50.
    View PubMed
29. McWilliams RR, Rabe KG, Olsold C, De Andrade M, Petersen GM. Risk of malignancy in first-degree relatives of patients with pancreatic carcinoma. Cancer 2005 Jul 15; 104(2):388-94.
    View PubMed
30. Couch FJ, Johnson MR, Rabe K, Boardman L, McWilliams R, de Andrade M, Petersen G. Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res 2005 Jan 15; 65(2):383-6.
    View PubMed
31. Nesbit MA, Bowl MR, Harding B, Ali A, Ayala A, Crowe C, Dobbie A, Hampson G, Holdaway I, Levine MA, McWilliams R, Rigden S, Sampson J, Williams AJ, Thakker RV. Characterization of GATA3 mutations in the hypoparathyroidism, deafness, and renal dysplasia (HDR) syndrome. J Biol Chem 2004 May 21; 279(21):22624-34.
    View PubMed
32. Nesbit MA, Bowl MR, Harding B, Ali A, Ayala A, Crowe C, Dobbie A, Hampson G, Holdaway I, Levine MA, McWilliams RR, Rigden S, Sampson J, Williams A, Thakker RV. Characterization of GATA3 mutations in the hypoparathyroidism, deafness and renal dysplasia (HDR) syndrome. J Biol Chem 2004 May 21; 279:22624-34.
    View PubMed
33. McWilliams R, Ayala AA, Ding C, Levine MA. The HDR Syndrome: an example of a complex developmental disorder associated with hypoparathyroidism. Clinical Cases in Mineral and Bone Metabolism 2004; 1(2):133-6.
34. McWilliams R, Ayala AA, Ding C, Levine MA. The HDR syndrome: an example of a complex developmental disorder associated with hypoparathyroidism. Clinical Cases in Mineral and Bone Metabolism 2004; 1(2):133-6.
    View PubMed
35. McWilliams RR, Brown PD, Buckner JC, Link MJ, Markovic SN. Treatment of brain metastases from melanoma. Mayo Clin Proc 2003 Dec; 78(12):1529-36.
    View PubMed
36. McWilliams RR, Giannini C, Hay ID, Atkinson JL, Stafford SL, Buckner JC. Management of brain metastases from thyroid carcinoma: a study of 16 pathologically confirmed cases over 25 years. Cancer 2003 Jul 15; 98(2):356-62.
    View PubMed